In the AWARD 11 trial, patients using semaglutide (1 mg weekly) achieved greater weight reduction than those using dulaglutide (3 mg weekly), with a mean difference of approximately 0.24% points
In the SURMOUNT-4 trial, participants who stopped tirzepatide regained a large share of their lost weight, while those who continued maintained and even extended their loss
These offerings build on Shed's mission to offer straightforward tools that support how the body actually works
Results indicated that power output was up to 15% higher following the glycine propionyl-l-carnitine trials compared to placebo, while post-exercise blood lactic acid was 15-16% lower compared to placebo
Beyond the safety issues, no one can live on 500 calories a day long term, and lasting results come from changes you can actually sustain, like choosing lower-glycemic foods over high-glycemic carbs or walking after dinner
What the STEP 1 body-composition analysis found An exploratory DXA analysis included 140 STEP 1 participants, of whom 95 received semaglutide